Douglas Hunt
Conseiller Juridique Général chez PUMA BIOTECHNOLOGY, INC.
Fortune : 305 116 $ au 31/05/2024
Profil
Douglas Hunt is currently the Chief Regulatory Affairs Officer at Puma Biotechnology, Inc. He previously worked as the Executive Director-Therapeutic Area at Amgen, Inc. from 2000 to 2008.
From 2008 to 2015, he served as the Vice President-Global Regulatory Affairs at Baxter Healthcare Corp.
He then worked as the VP-Regulatory Affairs & Quality Assurance at ArmaGen, Inc. from 2015 to 2017.
Mr. Hunt completed his undergraduate degree at the University of Portsmouth.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PUMA BIOTECHNOLOGY, INC.
0,16% | 22/04/2024 | 79 251 ( 0,16% ) | 305 116 $ | 31/05/2024 |
Postes actifs de Douglas Hunt
| Sociétés | Poste | Début |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Conseiller Juridique Général | 01/01/2018 |
Anciens postes connus de Douglas Hunt
| Sociétés | Poste | Fin |
|---|---|---|
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Conseiller Juridique Général | 01/12/2017 |
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Conseiller Juridique Général | 01/01/2015 |
| AMGEN INC. | Corporate Officer/Principal | 01/07/2008 |
Formation de Douglas Hunt
| University of Portsmouth | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
